Japanese women top global life expectancy for 40th straight year
Their average life expectancy was 87.13 years, a slight drop of 0.01 year from 2023. Men's life expectancy remained unchanged at 81.09, but their global ranking slipped to sixth from fifth, the Ministry of Health, Labor and Welfare said.
Japan was followed in the global ranking for women by South Korea at 86.40 and Spain at 86.34. Among men, Sweden ranked first at 82.29, followed by Switzerland at 82.20 and Norway at 81.59, the ministry said.
Life expectancy for both men and women declined in 2021 and 2022, due largely to the impact of the COVID-19 pandemic, but rebounded in 2023.
© KYODO
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yomiuri Shimbun
23 minutes ago
- Yomiuri Shimbun
New Pharmaceuticals Overseas: Change Situation in Which Foreign Drugs are Not Available in Japan
If groundbreaking new drugs are available overseas but cannot be used in Japan, it puts many patients at a disadvantage. This situation must be changed immediately. Cases referred to as 'drug loss,' in which pharmaceuticals newly approved in other countries do not become available in Japan, are increasing. For some time now, new drugs developed by overseas pharmaceutical companies have tended to face delays in being introduced to Japan, due to this country's complicated application procedures for approval and additional clinical trials targeting Japanese patients. This problem has been dubbed 'drug lag.' The government's efforts to proceed with measures, such as strengthening the review system, have reduced delays. Instead of drug lag, however, there is now an increase in cases of drug loss. This is because more overseas companies have not even applied for approval of their products in Japan in recent years, making the situation even more serious. Behind this lies a drastic change in development methods for pharmaceuticals. Advances in life sciences have led to the production of complex biopharmaceuticals using genes and cells, shifting the primary developers from major pharmaceutical manufacturers to emerging companies. Many of them are small businesses, so they are not adequately established to expand globally. Furthermore, in Japan, there is a strong tendency to lower the prices of drugs to curb medical expenses. This may lead many overseas drugmakers to make a business decision that there is little advantage to paying the high costs required to enter the Japanese market. Traditionally, drug loss has been conspicuous for rare ailments and pediatric diseases. However, now that the problem will likely expand to more common diseases such as breast cancer and diabetes, it is feared that patients in Japan will be unable to widely benefit from new drugs that are available overseas. To bring drugs developed overseas to Japan, it is necessary to provide more information to drugmakers and lower hurdles to applying for approval in Japan. To support U.S. companies in their applications, the Health, Labor and Welfare Ministry has established an office in the United States to assist them with the review process. It is also essential to establish a system that maintains prices that reflect the value of new pharmaceuticals. In addition to attracting overseas makers, this would also promote technological innovation in the pharmaceutical industry as a whole. However, public health cannot be steadily protected in Japan through an approach that relies on overseas companies. It is necessary to increase the number of new drugs originating in Japan. Japan's research capabilities are not low, but universities and other institutions find it difficult to directly link their research results to businesses, and this environment is hindering the improvement of pharmaceutical development capabilities. In the United States, many universities, startups and investors are concentrated in Boston to work together to produce a steady stream of new drugs. In Japan as well, it is important to create a similar hub, described as an ecosystem, for advanced academic-industrial collaboration. (From The Yomiuri Shimbun, July 28, 2025)
Japan Today
2 days ago
- Japan Today
Japanese women top global life expectancy for 40th straight year
Japanese women had the highest life expectancy in the world in 2024, marking the 40th consecutive year at the top, government data showed Friday. Their average life expectancy was 87.13 years, a slight drop of 0.01 year from 2023. Men's life expectancy remained unchanged at 81.09, but their global ranking slipped to sixth from fifth, the Ministry of Health, Labor and Welfare said. Japan was followed in the global ranking for women by South Korea at 86.40 and Spain at 86.34. Among men, Sweden ranked first at 82.29, followed by Switzerland at 82.20 and Norway at 81.59, the ministry said. Life expectancy for both men and women declined in 2021 and 2022, due largely to the impact of the COVID-19 pandemic, but rebounded in 2023. © KYODO
Yomiuri Shimbun
2 days ago
- Yomiuri Shimbun
Japan Average Life Expectancy Flat in 2024
Tokyo, July 25 (Jiji Press) — The average life expectancy of Japanese citizens born in 2024 remained almost unchanged from the previous year, a health ministry survey showed Friday. It stood at 81.09 years for men and 87.13 years for women. The average life expectancy indicates a future average lifespan for children born in a particular year. It is calculated on the premise that mortality rates at each age will not change. The country's life expectancy declined in 2021 and 2022, due to the COVID-19 crisis, after continuing to climb generally since the ministry started the survey in 1947. It rebounded in 2023 as the number of deaths from the disease dropped. The life expectancy of Japanese men placed sixth globally in 2024, after Sweden, Switzerland, Norway, Italy and Spain, dropping one place from 2023. That of Japanese women remained in first spot, followed by South Korea, Spain, Switzerland, France and Italy. The share of Japanese men born in 2024 who are projected to live until 75 and 90 stands at 75.3 % and 25.8%, respectively. Of women born last year, 87.9% are expected to live until 75 and 50.2% until 90. The ministry also predicted the causes of death for people born in 2024, with 25.59% of men, the largest group, seen dying of cancer, and 20.75% of women, the highest share, likely to pass away due to old age, higher than 19.06% for cancer deaths. If no one dies of cancer, life expectancy would rise 3.11 years for men and 2.68 years for women, the ministry said.
